Connect with us
  • Elysium

News

Pen which gives Parkinson’s early warning prepares for roll-out

Published

on

The NeuroMotor Pen has been in development for over 10 years

A digital pen which provides early warning of Parkinson’s disease and other neurological conditions has secured £1.2m funding to support its international roll-out.

The NeuroMotor Pen is set to launch later this year, initially focusing on the UK and Benelux markets, while also progressing work to secure regulatory approval to start selling in US.

The pen has passed clinical trials with the NHS in the North East of England and Scotland and is currently being used by Northumbria NHS Foundation Trust, and advanced talks to supply the pens to a UK-based primary care group are currently underway, following a development contract with NHS England to develop a version that can be used in GP surgeries.

The NeuroMotor Pen has been devised by Edinburgh medtech company Manus Neurodynamica.

Led by CEO Rutger Zietsma, Manus has spent over ten years developing the product, from concept through to manufacture and roll-out.

It works by employing sensors linked with analytical software which analyses the slightest limb and hand movements to help doctors assess whether a patient has early signs of Parkinson’s or other neurological conditions.

As well as providing a quick, inexpensive, non-invasive and objective aid to diagnosis, the CE-marked product also helps with the ongoing monitoring of those conditions.

In January last year, the firm signed a five-year contract with stationery brand Stabilo to manufacture the pens in Germany.

The invention, which has secured funding rounds totalling £5m to date to support its development in being able to benefit people with neurological conditions. Around 145,000 people are estimated to live with Parkinson’s in the UK alone and it the fastest-growing neurological condition in the world.

Investors in its latest £1.2m round included North East Innovation Fund, supported by the European Regional Development Fund and managed by Northstar Ventures, profit with purpose investor SIS Ventures and Old College Capital, the University of Edinburgh’s venture fund.

Dr. Rutger Zietsma, CEO of Manus

“2021 looks set to be an extremely busy year for Manus,” says Dr Zietsma.

“Having spent more than ten years developing, trialling and refining our first product, we can finally look forward to seeing our NeuroMotor Pens implemented more broadly and making a real difference to the lives of people living with Parkinson’s and other neurological conditions.

“Through faster and simpler diagnoses and objective patient monitoring with digital record keeping, we can help streamline the pathway and deliver more successful treatment outcomes for the fastest growing neurological condition in the world.”

Rob Halliday, fund manager, SIS Ventures says: “Manus is one of Scotland’s most promising early stage medtech companies, with the potential to make a huge impact.

“With its disruptive technology, mission-led approach, and ambitious management team, Manus is exactly the kind of business we look to invest in at SIS Ventures.

“Working along with the other investors, we’re very pleased to support Rutger and his team through their next phase of growth and impact creation.”

Rick Charnley, investment manager, Northstar Ventures, adds: “Having originally been involved with the company via a previous investment used to develop the initial prototype, we’ve been impressed with the team’s enhanced mission and are delighted to support the company further.

“We’re big believers in the impact Medtech companies like Manus can have on an ageing society.”

News

New company launched to drive forward Parkinson’s research

Published

on

Up to £800,000 will be invested over the next two years

Charity Parkinson’s UK is to launch a new company dedicated to driving forward research into Parkinson’s disease.

Vivifi Biotech has been created to lead and plan preparations for a new trial into the role of the restorative protein glial cell-derived neurotrophic factor (GDNF) in Parkinson’s.

Launched through the charity’s drug development arm, Parkinson’s Virtual Biotech, up to £800,000 will be invested over the next two years as efforts continue to find a life-changing new treatment for people living with the disease.

Plans for a new trial build on the initial groundbreaking clinical investigations in GDNF, the results of which proved inconclusive but did show some signs that the treatment may have started to regenerate participants’ dopamine-producing brain cells.

“The unwavering passion and determination of the GDNF participant group has ensured that the potential of GDNF, and the role of patients in research, has never been forgotten,” says Paul Jackson Clark, director of engagement at Parkinson’s UK.

“They’ve tirelessly campaigned, fundraised and shared their experience with us, enabling us all to get to this monumental point.

“We now have the chance to see if we can find a life-changing new treatment that people with Parkinson’s desperately need. There are still plenty of obstacles but this announcement gives us the opportunity to move things forward together.”

Parkinson’s UK was the major funder of the initial trial, which investigated whether boosting levels of GDNF could slow, stop or reverse the progression of Parkinson’s.

Tom Phipps was a participant in the GDNF trial.

“My outcome was as positive as I could have wished for, I feel the trial brought me some time and has delayed the progress of my condition,” he says.

“The trial participants have always believed in GDNF’s potential,” said Parkinson’s UK in their announcement.

“So have we and the other organisations involved in the trial.

“Some participants tell us they’re still experiencing the benefits, years on from undergoing this experimental therapy. We’ve been working with them since the end of the trial.

“Together, we want to make sure we’ve explored every option.”

Continue Reading

Community rehab

Music group launched to support BAME community

Published

on

Leicester Musical Memory Box is launching its online music project Geet Sangeet

A music group established to support people living with dementia, memory loss and brain injury has received funding to launch an online project for the South Asian and BAME community.

Leicester Musical Memory Box (LMMBox) was founded in July 2018, and since that time has grown from one group in the city to six, providing interactive music sessions for people of all ages and backgrounds, including a group specific to the South Asian community.

The group – which has two staff members who are fluent in Gujarati, Hindi, Punjabi and Urdu – aims to provide the local community with a supportive network and a safe space to explore the unique challenges that a brain injury may bring to individuals, as well as their families and carers.

The new online music project is named ‘Geet Sangeet’ – translated as ‘Songs Sung Together’ – and will incorporate music and cultural references specific to the South Asian community, led by group leader Beena Masand from LMMBox.

Each session will begin with gentle exercises to warm up the body and brain, followed by singing and discussion about various music, songs, and media.

Attendees will also receive their own ‘musical memory box’ in a bag to help increase the interactivity of the sessions.

The project has received funding from the new Local Connections Fund, and is in collaboration with Headway Leicester.

Music has proven benefits for people with memory problems or a brain injury, including enabling people to connect with past experience and enabling freedom of expression, confidence and independence.

Attendance at the groups also helps to improve mood and reduce feelings of social isolation.

“We know we are providing a vital service to our members and receive enquiries regularly,” says Kyle Newman, group leader and co-director of LMMBox.

“In spite of the lockdown, we are thrilled to be able to once again provide a culturally specific group for the South Asian community.

“We also know that the group leader needs to come from that community and have the music and cultural knowledge to be able to engage participants effectively.”

“We are delighted to collaborate with LMMBox and reach out to more people across Leicester who have been affected by brain injury,” adds Mary Goulty, service manager at Headway Leicester.

“There is a clear need for a support service within the BAME community and that’s why we launched our BAME group last year, which is providing a vital lifeline to brain injury survivors we support and their families.”

To contact LMMBox, visit www.leicestermusicalmemorybox.co.uk

For support with brain injury in the Leicester community, visit www.headwayleicester.org.uk.

Continue Reading

News

Art Therapy offers an emotional outlet for those living with a Traumatic Brain Injury (TBI)

Published

on

Masks not only allow us to hide our true feelings but to also express them without fear of judgement.

Being able to ‘hide’ one’s true self, may be a way, for others, to truly ‘show’ themselves.

For this reason, Chroma therapists began delivering Art Therapy sessions online to those living with a Traumatic Brain Injury (TBI) in an attempt to help them express their emotions in a creative, non-threatening way.

A TBI can have devastating effects upon a person’s mental health, as well as physical, with emotional issues caused by significant, sudden changes in appearance and abilities.

Studies have found Art Therapy to be effective in helping TBI patients with emotional expression, socialisation, emotional adaptation to mental and physical disabilities, and communication in a creative and non-threatening way.1

Self-expression is fundamental in processing the effects of a TBI. Take a look at the image below.

On the left is the base mask. During the process of art therapy, across a number of sessions, the participant talks, reflects and begins to create ideas or metaphors which then get placed onto the base mask. Often this depicts the face he presents to the outside world, in contrast with the dual parts of to his inner personality including a bright peaceful side and a dark, tumultuous side.

Based on the sessions, Chroma therapists are better able to gauge the patient’s feelings, discuss the final piece and help the patient begin to process their emotions.

In effect, art therapy offers a creative gateway to communication and used in this way, tries to enable the participant to externalise their inner thoughts and feelings.

As a therapy, it has been shown to help reduce feelings of stress, promote creativity and imagination as well as increase self-expression, confidence and communication.

Chroma began delivering these sessions as a way to allow clients to reveal thoughts and feelings about themselves which they may find hard to express, or may not even be aware of, and which may be being expressed through more difficult behaviours.

They also create an opportunity for greater communication, allowing therapists to gain a deeper understanding of the client’s thoughts, anxieties and feelings.

Being able to express themselves creatively helps the client reveal their true feelings, which in itself can be cathartic – a relief to release their emotions, in a personal, safe space.

Chroma continues to deliver these sessions online to help reach as many TBI sufferers across the UK as possible in an attempt to help them begin to process their emotions concerning the effects the TBI had upon them, with the outlook to help improve their mental wellbeing which in turn will help promote a positive outlook to life and rehabilitation outcomes.

Continue Reading

Newsletter



Get the NR Times update

Trending